PolyMedix to Present at 5th International AIDS Society (IAS) Conference
Cape Town, South Africa
July 19 - 22, 2009
RADNOR, Pa.--(BUSINESS WIRE)--Jul 17, 2009 - PolyMedix, Inc. (OTC BB: PYMX, www.polymedix.com), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders based on biomimetics, will make a poster presentation at the 5th International AIDS Society Conference. The poster will be given by PolyMedix Scientific Advisor Dr. David Miller, on Tuesday, July 21, 2009 at the Cape Town International Conference Center in Cape Town, South Africa.
Titled “Developing new antibiotic approaches to controlling MDR/XDR TB in HIV patients on HAART”, the poster focuses on the mechanism of action of PolyMedix compounds and their activity against the tuberculosis bacterium, and why the Company believes bacterial drug resistance is unlikely to develop to these compounds. Record levels of multi-drug resistant tuberculosis (MDR) and extensively drug resistant tuberculosis (XDR-TB) were reported in 2007, with a 90% mortality rate among patients co infected with HIV/MDR-/XDR-TB.
Distinguishing them from other antibiotic compounds currently on the market, PolyMedix's compounds are synthetic chemical mimics of host defense proteins, one of the oldest and most effective antimicrobial defense systems found in virtually all living creatures. PolyMedix's compounds are the first and only known small molecule mimetics of host defense proteins intended to treat systemic infections. They have a novel mechanism of action, the direct biophysical disruption of bacterial cell membranes, which the Company believes makes development of bacterial resistance unlikely.
PolyMedix's lead defensin-mimetic antibiotic compound, PMX-30063, is currently in Phase I human clinical testing. On December 10, 2008, PolyMedix announced the results and successful outcome of the first Phase I human clinical study with PMX-30063. On June 5, 2008 PolyMedix announced the commencement of dosing in a second clinical trial, a Phase IB study, with PMX-30063. PolyMedix plans to develop PMX-30063 as a pan-Staph agent, for the broad treatment of many forms of Staphylococcus infections. The compounds described in the IAS poster, which share the same mechanism of action as PMX-30063, represent new molecules for possible development as potential treatments for tuberculosis.
PolyMedix believes that the development of new therapeutic options for treating susceptible as well as MDR/XDR TB is predictably the most effective way to significantly decrease global morbidity related to HIV infection. PolyMedix has developed a series of small, non-peptidic antimicrobial compounds effectively mimicking the activity of host defense proteins, three of which have exhibited high antimicrobial activity against, and selectivity for, the H37Rv strain of M. tuberculosis. Emerging structure-activity relationships suggest promising medicinal chemistry approaches to optimize activity and selectivity against M. tuberculosis. There is an urgent need for developing novel anti-TB drugs active against MDR/XDR strains, requiring shorter treatment duration times that do not interfere with existing HIV therapies and thwart bacterial responses leading to drug resistance.
About the Conference
The 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2009) in Cape Town, South Africa is the world's largest open scientific conference on HIV/AIDS and is organized by the IAS, in partnership with South African-based NGO, Dira Sengwe, organizer of the series of South African AIDS Conferences. Held every two years, the conference attracts about 5,000 delegates from all over the world. It is an opportunity for the world's leading scientists, clinicians, public health experts and community leaders to examine the latest developments in HIV-related research, and to explore how scientific advances can, in practical ways, inform the global response to HIV/AIDS.
For more information on the conference please see the website
About PolyMedix, Inc.
PolyMedix is a publicly traded emerging biotechnology company focused on the development of novel drugs and biomaterials for the treatment of infectious diseases and acute cardiovascular disorders. PolyMedix's compounds are based on biomimetics: non-peptide small molecule drug candidates that mimic the activity of proteins. The Company's antibiotic compounds, including PMX-30063 – small molecule mimetics of human host-defense proteins - have a mechanism of action distinct from those of current antibiotic drugs, a mechanism which is intended to make bacterial resistance unlikely to develop. The Company's goal is to develop these as rapidly acting antibiotics for serious systemic and local infections. The Company plans to continue the development of polymeric formulations as antimicrobial biomaterials, which can be used as additives to paints, plastics, and textiles to create self-sterilizing products and surfaces. The Company's heptagonist compounds, including PMX-60056, reverse the activity of both heparin and Low Molecular Weight Heparins, with the goal of developing an antagonist drug that is safer and easier to use than currently approved therapy for heparin. For more information, please visit PolyMedix on its website at www.polymedix.com.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause PolyMedix's actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. PolyMedix has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends”, “goal”, “potential,” “may,” ”suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements, PolyMedix's compounds may not enter or successfully complete clinical testing or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these factors is included in PolyMedix's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. PolyMedix undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
Contact: PolyMedix, Inc.
Lona Cornish, 484-598-2340
The Investor Relations Group
Erika Moran, 212-825-3210
Janet Vasquez, 212-825-3210
Posted: July 2009